PMID- 17229509
OWN - NLM
STAT- MEDLINE
DCOM- 20070626
LR  - 20070330
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 31
IP  - 3
DP  - 2007 Apr 13
TI  - An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like 
      effects in an olfactory bulbectomy model.
PG  - 622-7
AB  - Olfactory bulbectomized (OB) rats have been considered to serve as a useful 
      animal model of depression in terms of behavioral, neurochemical, and 
      neuroendocrine alterations, which reflect symptoms of patients with major 
      depression. These behavioral and neurochemical changes in OB rats are normalized 
      by the chronic administration of antidepressants. Recently, it has been reported 
      that the compounds acting on stress-related peptide receptors such as an arginine 
      vasopressin 1b (V(1b)) receptor antagonist and corticotropin-releasing factor 
      (CRF) 1 receptor antagonists have antidepressant-like effects in several animal 
      models. Here, the effects of acute and chronic (14 days) treatment with a V(1b) 
      receptor antagonist (SSR149415) and a CRF1 receptor antagonist (CP-154,526) were 
      examined in olfactory bulbectomy-induced hyperemotionality. Oral acute treatment 
      with SSR149415 or CP-154,526 did not affect olfactory bulbectomy-induced 
      hyperemotionality. In contrast, oral chronic treatment with SSR149415 (10 and 30 
      mg/kg) or CP-154,526 (10 mg/kg) significantly reduced hyperemotionality. The 
      present results suggest that stress-related peptides such as arginine vasopressin 
      and CRF might be implicated in olfactory bulbectomy-induced hyperemotionality. 
      Furthermore, blockade of the V(1b) receptor or the CRF1 receptor may be useful in 
      treating subjects suffering from chronic stressful conditions.
FAU - Iijima, Michihiko
AU  - Iijima M
AD  - Psychiatric Diseases and Pain Research, Medicinal Pharmacology Laboratory, 
      Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 
      Yoshino-cho, Kita-ku, Saitama, Saitama 331-9530, Japan.
FAU - Chaki, Shigeyuki
AU  - Chaki S
LA  - eng
PT  - Journal Article
DEP - 20061215
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 
      (1-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide)
RN  - 0 (Antidepressive Agents)
RN  - 0 (CP 154526)
RN  - 0 (Indoles)
RN  - 0 (Pyrimidines)
RN  - 0 (Pyrroles)
RN  - 0 (Pyrrolidines)
SB  - IM
MH  - Animals
MH  - Antidepressive Agents/*therapeutic use
MH  - Depression/*drug therapy/etiology
MH  - Disease Models, Animal
MH  - Drug Administration Schedule
MH  - Indoles/*therapeutic use
MH  - Male
MH  - Olfactory Bulb/physiology/surgery
MH  - Pyrimidines/therapeutic use
MH  - Pyrroles/therapeutic use
MH  - Pyrrolidines/*therapeutic use
MH  - Rats
MH  - Rats, Wistar
MH  - Statistics, Nonparametric
EDAT- 2007/01/19 09:00
MHDA- 2007/06/27 09:00
CRDT- 2007/01/19 09:00
PHST- 2006/10/03 00:00 [received]
PHST- 2006/11/13 00:00 [revised]
PHST- 2006/12/09 00:00 [accepted]
PHST- 2007/01/19 09:00 [pubmed]
PHST- 2007/06/27 09:00 [medline]
PHST- 2007/01/19 09:00 [entrez]
AID - S0278-5846(06)00443-X [pii]
AID - 10.1016/j.pnpbp.2006.12.008 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):622-7. doi: 
      10.1016/j.pnpbp.2006.12.008. Epub 2006 Dec 15.